QC
SRPT icon

Quent Capital’s Sarepta Therapeutics SRPT Stock Holding History

Quent Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16K Buy
735
+324
+79% +$6.27K ﹤0.01% 1050
2025
Q4 		$8.85K Buy
411
+79
+24% +$1.67K ﹤0.01% 1181
2025
Q3 		$6.4K Buy
+332
New +$5.92K ﹤0.01% 1102
2025
Q2 		– Sell
-16
Closed -$1.02K – 1108
2025
Q1 		$1.02K Hold
16
– – ﹤0.01% 1210
2024
Q4 		$1.95K Hold
16
– – ﹤0.01% 1173
2024
Q3 		$2K Hold
16
– – ﹤0.01% 1225
2024
Q2 		$2.53K Buy
16
+3
+23% +$385 ﹤0.01% 1188
2024
Q1 		$1.68K Buy
13
+11
+550% +$1.35K ﹤0.01% 1248
2023
Q4 		$193 Sell
2
-95
-98% -$9.11K ﹤0.01% 1307
2023
Q3 		$11.8K Sell
97
-17
-15% -$1.92K ﹤0.01% 902
2023
Q2 		$13.1K Hold
114
– – ﹤0.01% 880
2023
Q1 		$15.7K Buy
114
+97
+571% +$12.6K ﹤0.01% 829
2022
Q4 		$2.2K Buy
+17
New +$1.97K ﹤0.01% 1134

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quent Capital's SRPT Position: Q1 2026 in Review

Quent Capital increased its Sarepta Therapeutics (SRPT) stake by 79% in Q1 2026, buying an estimated $6.27K and bringing the position to 735 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #1050.

Quent Capital first reported a position in SRPT in Q4 2022 and has held it in 13 quarters since. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Quent Capital held 735 shares of Sarepta Therapeutics worth $16K as of Q1 2026.
  • Quent Capital bought 324 Sarepta Therapeutics shares in Q1 2026, an estimated $6.27K.
  • Sarepta Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q1 2026, its #1050 holding.
  • Quent Capital first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.